Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Helsinn Group, Actelion Pharma Enter Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Helsinn Group, Actelion Pharma Enter Agreement

For worldwide rights to Valchlor®, a treatment of mycosis fungoides-type cutaneous T-cell lymphoma

By: Betsy Louda

, Contract Pharma

Helsinn has entered into an agreement to acquire worldwide rights to Actelion Pharmaceuticals’ Valchlor®/Ledaga®, (mechlorethamine/chlormethine) an alkylating agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). 

 

Valchlor® is the first and only FDA-approved topical formulation of mechlorethamine. It was launched in the U.S. at the end of 2013 and sales have grown from $11 million in 2014 to $35 million globally in 2017. In the U.S., approximately 15,000 patients are currently diagnosed with stage IA-IB MF-CTCL, qualifying it as a rare or orphan disease. 

 

Riccardo Braglia, Helsinn Group vice chairman and chief executive officer, said, “Helsinn is delighted to announce the acquisition of Valchlor®/Ledaga®, for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. This is a discomforting disease which has a significant impact on patients’ quality of life. Helsinn is committed to developing and marketing products designed to help people with cancer get the most out of every day and benefit from Valchlor®, which is approved and marketed in the U.S. where limited treatment choices are available. We are excited to be adding this drug to our portfolio of products designed to offer appropriate cancer therapeutic and supportive care treatment options to patients. We are looking forward to bringing the drug to more patients worldwide”.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters